HLL Lifecare to Set up Vaccine Plant in Tamil Nadu

Indian healthcare firm, HLL (formerly, Hindustan Latex Limited) Lifecare Ltd. has floated a wholly owned subsidiary — HLL Biotech Ltd. — to execute a new project that aims to boost the country’s vaccine security.

The first phase of IVC, coming up at Chengalpattu in Tamil Nadu's Kanchipuram district, will be completed in 36 months.

With an annual capacity of 585 million doses, the unit will manufacture pentavalent combination (DPT plus Hep B plus Hib), BCG, measles, hepatitis B, human rabies, Hib and Japanese encephalitis vaccines in the first phase.

"The total project cost is Rs 594 crore, of which Rs 28 crore has already been released. We have also started on site preliminary works at the 100 acre area. Project office has started functioning with sufficient staff including the project officer," HLL CMD M Ayyappan said.